Highlights Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Market Closed - OTC Markets Other stock markets 01:12:14 22/05/2024 am IST			5-day change	1st Jan Change
0.0377 ^USD	-2.73%		-3.33%	-1.57%

12/04	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
25/03	Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/04	CI
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	25/03	CI
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	15/11	MT
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19/23/19	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/23/22	CI
Oncotelic Launches PDAO SEC chatbot	24/23/24	CI
ONCOTELIC THERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20/23/20	AQ
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology	19/23/19	CI
ONCOTELIC THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	15/23/15	AQ
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem	13/23/13	CI
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer	06/23/06	CI
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer	25/23/25	AQ
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer	25/23/25	CI
Oncotelic Announces the launch of PDAO token	17/23/17	AQ
Oncotelic Therapeutics, Inc. Announces Launch of Wholly Owned Subsidiary, Pet2DAO Inc. and its Associated Token PDAO	17/23/17	CI
ONCOTELIC THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03/23/03	AQ
Oncotelic Issues Year End Message to Shareholders	28/22/28	AQ
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022	19/22/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Highlights

Filters